MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new
MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new radiopharmaceutical, 123I-BMIPP (123I-beta-methyl-iodophenylpentadecanoic acid), for detection of cardiac ischemia in the emergency department. The cardiac imaging pharmaceutical will be manufactured at MDS Nordion's cyclotron facility in Vancouver, BC.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.